NEW
YORK, May 20, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of AbbVie Inc. (NYSE:
ABBV).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/abbvie-inc-loss-submission-form/?id=27457&from=4
The lawsuit seeks to recover losses for shareholders who
purchased AbbVie between April 30,
2021 and August 31, 2021.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
June 6, 2022 to petition the
court. Your ability to share in any recovery doesn't require that
you serve as a lead plaintiff.
According to a filed complaint, AbbVie Inc. issued materially
false and/or misleading statements and/or failed to disclose that:
(1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to
Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor
drugs; (2) as a result, it was likely that the U.S. Food and Drug
Administration would require additional safety warnings for Rinvoq
and would delay the approval of additional treatment indications
for Rinvoq; and (3) therefore, defendants' statements about the
Company's business, operations, and prospects lacked a reasonable
basis.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/abbv-shareholder-alert-jakubowitz-law-reminds-abbvie-shareholders-of-a-lead-plaintiff-deadline-of-june-6-2022-301551322.html
SOURCE Jakubowitz Law